Article

Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United States

2024-07-18

Abstract excerpt

<title>Abstract</title> <p>Background Many neurologic or immune-mediated conditions have been evaluated as potential adverse events (AEs) in coronavirus disease 2019 (COVID-19) vaccine safety surveillance. To contextualize United States (US) surveillance findings, it is important to quantify the risk of neurologic or immune-mediated AEs associated with COVID-19 diagnosis among adults in the US before the introdu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4abad716-e968-5d47-8475-5f0ea3f47a47
DOI: 10.21203/rs.3.rs-4629616/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United StatesDOI 10.21203/rs.3.rs-4629616/v1Read

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillanceSemantic proximity Read

“Association between COVID-19 vaccination, infection, and risk of Guillain-Barre syndrome, Bell’s palsy, encephalomyelitis and transverse myelitis: a population-based cohort and self-controlled case series analysis”Semantic proximity Read

Association between COVID-19 Vaccination and Neuropsychiatric ConditionsSemantic proximity Read

Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemicSemantic proximity Read

Neurological Diagnoses in Hospitalized COVID-19 Patients Associated With Adverse Outcomes: A Multinational Cohort StudySemantic proximity Read

Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sourcesSemantic proximity Read

A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccinationSemantic proximity Read

Considerations for Causality Assessment of Neurological and Neuropsychiatric Complications of SARS-CoV-2 Vaccines: from Cerebral Venous Sinus Thrombosis to Functional Neurological DisorderSemantic proximity Read

Incidence and management of the main adverse effects reported after COVID-19 vaccinationSemantic proximity Read

Multinational Prevalence of Neurological Phenotypes in Patients Hospitalized with COVID-19Semantic proximity Read

Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19Semantic proximity Read

Self-Reported Adverse Events Following SARS-CoV-2 Vaccination: A Nationwide Questionnaire Study in the Adult Danish PopulationSemantic proximity Read